MYGN's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.85 -- higher than merely 19.55% of US-listed equities with positive expected earnings growth.
In terms of twelve month growth in earnings before interest and taxes, Myriad Genetics Inc is reporting a growth rate of -680.94%; that's higher than merely 2.89% of US stocks.
The volatility of Myriad Genetics Inc's share price is greater than that of 80.85% US stocks with at least 200 days of trading history.
If you're looking for stocks that are quantitatively similar to Myriad Genetics Inc, a group of peers worth examining would be HBIO, KVHI, DSS, CCUR, and DHX.
MYGN's SEC filings can be seen here. And to visit Myriad Genetics Inc's official web site, go to myriad.com.
Myriad Genetics discovers and commercializes molecular diagnostic tests that; determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties to improve patient care. The company was founded in 1991 and is based in Salt Lake City, Utah.
MYGN Price Forecast Based on DCF Valuation
DCF Fair Value Target:
We started the process of determining a valid price forecast for Myriad Genetics Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Myriad Genetics Inc ranked in the 18th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. In terms of the factors that were most noteworthy in this DCF analysis for MYGN, they are:
The company's compound free cash flow growth rate over the past 5.5 years comes in at -0.08%; that's greater than merely 18.67% of US stocks we're applying DCF forecasting to.
Myriad Genetics Inc's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at -14.82. This coverage rate is greater than that of just 6.49% of stocks we're observing for the purpose of forecasting via discounted cash flows.
The weighted average cost of capital for the company is 11. This value is greater than 87.45% stocks in the Healthcare sector that generate free cash flow.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as MYGN, try ARA, EW, PRGO, VAR, and VIVO.
Myriad Genetics, Inc. (MYGN), a leader in molecular diagnostics and precision medicine, announced today two recent publications validating the polygenic risk score (PRS) component of Myriad’s breast cancer risk stratification tool riskScore®. The publications clinically validate both the ability of the PRS component of riskScore to predict breast cancer risk in asymptomatic women and modify risk estimations for patients identified with pathogenic mutations.
Myriad Genetics, Inc. (MYGN), a leader in molecular diagnostics and precision medicine, today announced a new collaboration with OptraHEALTH® to implement a cognitive ChatBOT named Gene™ to provide genetic and financial assistance information to prospective patients. Gene is an AI-powered, HIPAA-compliant knowledge platform for genetic health with BOT interfaces and can answer over 500,000 health related questions pertaining to hereditary cancer. Gene interfaces with Myriad’s market leading online hereditary cancer quiz, which is now taken by approximately one million people per year.
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]